Like many others, the biopharma industry has been shaken by the rapid rise of the coronavirus outbreak. But unlike any other industry, biopharma can solve the growing threat through science and innovation.
Our journalists are working hard to deliver as much information as possible on the current crisis. If quality information and independent journalism also matter to you, don’t forget that you can support our journalists by becoming an Insider member. We’ve received encouragement from our community and we believe more than ever that we have a critical role to play in this crisis as a trusted source of information. To stay up to date with the last developments, you can also subscribe to our newsletter.
We will be updating this page on a regular basis so feel free to keep an eye on it and share it with your network.
Stay safe and keep reading good journalism.
As coronavirus disease sweeps the globe, a number of European healthcare organizations are stepping up to meet challenges in producing vaccines and diagnostics. All players in the scramble to develop Covid-19 vaccines are at the preclinical stage. It’s hard to say who is winning the race for a vaccine, but research supported by big pharma is getting the most attention.
As the coronavirus pandemic rages, drug development is becoming harder than ever, if arguably even more important. What is the extent of the issue, and how can companies protect their pipelines?
COVID-19 in the news
The collaboration will be led by the Parisian Institut Pasteur, whose vaccine technology — in this case modifying a measles virus vector to carry coronavirus antigens — is licensed to Themis. Themis will speed up the research by providing scaling and manufacturing muscle. Read more.
The money was awarded to help CureVac quickly scale up the production of its candidate Covid-19 vaccine. It came one day after allegations from the German newspaper Welt am Sonntag claiming that US President Donald Trump intended to acquire the vaccine for exclusive use in the US. Read more.
BioNTech has jumped to the front of the queue of European companies trying to get a vaccine for the coronavirus to market with an announcement of clinical testing at the end of next month and a big Chinese investment. Read more.
The clinical trial is designed to test Sensorion’s lead candidate drug in people with sudden sensorineural hearing loss, a rare disorder where the patient can go deaf within several days. The trial results were to be released late 2020, but the company now expects to release them in mid-2021. Read more.
BONUS! New to remote work? Read our advice:
Labiotech.eu was already familiar to remote work before the coronavirus forced us to work far from the office. Fortunately, we shared our best practice last year in a special article. If you are also struggling with disrupted work, feel free to read it and get inspired. Learn how to work remotely.